Digest Network Come funziona
Network
/
Società
Me
Non verificato

MedinCell

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

13 comunicati stampa

Guarda tutti i comunicati
11/11/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Mercato del lavoro
Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth
Fonte
MedinCell
Emittente
Business Wire
1.00
0
10/11/2025
Associazioni/Professionisti
Salute
Finanza
Medicina - Varie
Farmaceutica
Biotecnologia
Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark
Fonte
MedinCell
Emittente
Business Wire
1.00
0
10/02/2025
Biotecnologia
Psichiatria
Salute
Farmaceutica
Medicina - Varie
Industria
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
Fonte
MedinCell
Emittente
Business Wire
1.00
0
12/12/2024
Biotecnologia
Psichiatria
Salute
Farmaceutica
Medincell to Join the Euronext SBF 120 Index
Fonte
MedinCell
Emittente
Business Wire
1.00
0
09/12/2024
Industria
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement
Fonte
MedinCell
Emittente
Business Wire
1.00
0
06/11/2024
Pubblico Esercizio/Vendita al dettaglio
Industria
Mercato del lavoro
Web e Social Network
Telefonia e Varie
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3
Fonte
MedinCell
Emittente
Business Wire
1.00
0
04/11/2024
Mercato del lavoro
Fiere
Industria
Psichiatria
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Medincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241
Fonte
MedinCell
Emittente
Business Wire
1.00
0
23/09/2024
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Medincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®
Fonte
MedinCell
Emittente
Business Wire
1.00
0
23/09/2024
Eventi
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Medincell’s Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia
Fonte
MedinCell
Emittente
Business Wire
1.00
0
05/09/2024
Industria
Biotecnologia
Psichiatria
Salute
Farmaceutica
Medicina - Varie
Medincell’s Partner Teva Provides New Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI)
Fonte
MedinCell
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0